Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

Item

http://www.wikidata.org/entity/Q35687851

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

@ast

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

@en

type

Item

label

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

@ast

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

@en

prefLabel

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

@ast

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.

@en

P1476

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer

@en

P2093

Belinda Lategan

http://www.w3.org/2001/XMLSchema#string

Elvira del Barco

http://www.w3.org/2001/XMLSchema#string

Francisco Vera-Badillo

http://www.w3.org/2001/XMLSchema#string

Ignacio Cruz

http://www.w3.org/2001/XMLSchema#string

Juan J Cruz

http://www.w3.org/2001/XMLSchema#string

Martin C Chang

http://www.w3.org/2001/XMLSchema#string

Melissa Chan

http://www.w3.org/2001/XMLSchema#string

Paula Quesada

http://www.w3.org/2001/XMLSchema#string

Robyn Goldstein

http://www.w3.org/2001/XMLSchema#string

Rosa González

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.

P304

e0132449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0132449

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Ocana

Eitan Amir

P577

2015-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280031020

http://www.w3.org/2001/XMLSchema#string

P698

26161666

http://www.w3.org/2001/XMLSchema#string

P921

progesterone-receptor positive breast cancer

P932

4498889

http://www.w3.org/2001/XMLSchema#string